Tech Company Financing Transactions
Immune-Onc Therapeutics Funding Round
Immune-Onc Therapeutics closed a Series B funding round on 9/20/2018. Backers included Northern Light Venture Capital, StartX and Vivo Capital.
Transaction Overview
Company Name
Announced On
9/20/2018
Transaction Type
Venture Equity
Amount
Unknown
Round
Series B
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
795 San Antonio Rd.
Palo Alto, CA 94303
USA
Palo Alto, CA 94303
USA
Phone
Undisclosed
Website
Email Address
Overview
Immune-Onc Therapeutics, Inc. is a newly established biopharmaceutical company focused on developing innovative therapeutic antibodies for cancer treatment.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Charlene Liao
Chief Medical Officer
Paul Woodard
Founder
Guo-Liang Yu
VP - Bus. Development
Ji Li
VP - Bus. Development
An Song
Browse more venture capital transactions:
Prev: 9/20/2018: The/Studio venture capital transaction
Next: 9/20/2018: GitLab venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs